Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult ...

) has been revised to $6.12 / share. This is an increase of 100.00% from the prior estimate of $3.06 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand ...

Fintel reports that on September 23, 2025, Maxim Group upgraded their outlook for Citius Oncology (NasdaqCM:CTOR) from Hold to Buy. As of September 13, 2025, the average one-year price target for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Find the latest Citius Oncology, Inc. (CTOR) stock quote, history, news and other vital information to help you with your stock trading and investing.